Overview
This is a Prospective Observational Cohort Study, designed specifically to investigate racial differences in toxicities and treatment outcomes of cancer patients treated with immune checkpoint inhibitors (ICIs). ICIs are a powerful and innovative mode of cancer therapy. Their use has increased dramatically over the past 5 years. However, little data has been collected about ICI treatment response among patients of African ancestry (AA). In addition, little is known about the toxicities, treatment patterns, long-term outcomes, and post-treatment quality of life associated with ICIs outside the clinical trials setting. A prospective cohort study with a focus on this real-world question of racial differences between AA patients and patients of European ancestry (EA) in real-world community oncology
settings could address these knowledge gaps.
Key Inclusion Criteria
For a patient to be eligible for participation in this study, all of the following criteria must apply.
- Be 18 years of age or older
- Self-identify as African/African American/Black (AA), or European American/ Caucasian/white (EA)
- Patients may identify a Hispanic/Latino ethnicity in combination with an AA or
EA racial identity
- Patients may identify a Hispanic/Latino ethnicity in combination with an AA or
- Have a current diagnosis of invasive cancer at stage I-IV
- Patients may have a history of previous cancer diagnosis and cancer treatment
not involving immunotherapy - Be scheduled to receive anti-PD-1/-L1 ICI-containing therapy according to FDA labels or
NCCN guidelines at Category 1 or 2A as standard of care treatment alone or in
combination with co-treatments (including alternative ICIs) - Be able to speak and read English or Spanish
- Be able to provide written or remote informed consent
Key Exclusion Criteria
A patient will not be eligible for participation in this study if any of the following criteria apply.
- Identify as Asian, Pacific Islander, or American Indian/Alaskan Native
- Be diagnosed with melanoma (because melanoma is very rare in AAs)
- Currently participate or plan to participate in any other cancer treatment trials
- Have received prior immunotherapy for cancer, including checkpoint inhibitors, CAR-T therapy, and/or cytokine therapy
Learn More
Study Type
N/A
Principal Investigator(s)
Michael Humeniuk, MD
Sponsor(s)
University of Rochester Cancer Center (URCC)